Cargando…

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

BACKGROUND: RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rouphael, Nadine G., Morgan, Cecilia, Li, Shuying S., Jensen, Ryan, Sanchez, Brittany, Karuna, Shelly, Swann, Edith, Sobieszczyk, Magdalena E., Frank, Ian, Wilson, Gregory J., Tieu, Hong-Van, Maenza, Janine, Norwood, Aliza, Kobie, James, Sinangil, Faruk, Pantaleo, Giuseppe, Ding, Song, McElrath, M. Juliana, De Rosa, Stephen C., Montefiori, David C., Ferrari, Guido, Tomaras, Georgia D., Keefer, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2019
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819112/ https://www.ncbi.nlm.nih.gov/pubmed/31566579 http://dx.doi.org/10.1172/JCI128699

Ejemplares similares

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial
por: Pérez-Losada, Marcos, et al.
Publicado: (2009)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
por: Seaton, Kelly E., et al.
Publicado: (2014)

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
por: Gray, Matthew D., et al.
Publicado: (2022)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017)

Length variation in HIV-1 gp120 as the product of DNA misalignment mechanism
por: Guglietta, Silvia, et al.
Publicado: (2010)

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
por: Balasubramanian, Preetha, et al.
Publicado: (2018)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

A single gp120 residue can affect HIV-1 tropism in macaques
por: Del Prete, Gregory Q., et al.
Publicado: (2017)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
por: Wang, Shixia, et al.
Publicado: (2017)

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques
por: Jones, Andrew T., et al.
Publicado: (2018)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Physiological Corticosterone Attenuates gp120-Mediated Microglial Activation and Is Associated with Reduced Anxiety-Like Behavior in gp120-Expressing Mice
por: Moss, Emaya M., et al.
Publicado: (2023)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

Internalization and Axonal Transport of the HIV Glycoprotein gp120
por: Berth, Sarah, et al.
Publicado: (2015)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet
por: Schiavone, Marco, et al.
Publicado: (2012)

Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
por: Drummer, Heidi E., et al.
Publicado: (2013)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
por: Edupuganti, Srilatha, et al.
Publicado: (2020)

Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 ± IL-15
por: McKee, Hayley J, et al.
Publicado: (2004)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate
por: Stansell, Elizabeth, et al.
Publicado: (2015)

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
por: Chua, Joel V., et al.
Publicado: (2021)

P14-11. Educating community medical providers about HIV vaccine induced seropositivity
por: Mark, KE, et al.
Publicado: (2009)

Macrophage–sensory neuronal interaction in HIV-1 gp120-induced neurotoxicity(‡)
por: Moss, P. J., et al.
Publicado: (2015)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

Behavioral Evidence for a Tau and HIV-gp120 Interaction
por: Vijayan, Murali, et al.
Publicado: (2022)

Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides
por: Kassler, Kristin, et al.
Publicado: (2011)

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens
por: Karasavvas, Nicos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2qbhfj2ak6q4nhfms45vcsmefm